This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the business of biotechnology, a rising tide can ...

A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed versus analyst expectations, triggering a 50% stock drop and highlighting sector skepticism. Key hurdles for Compass ...

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...